About this Journal Submit a Manuscript Table of Contents
ISRN Oncology
Volume 2013 (2013), Article ID 729819, 7 pages
http://dx.doi.org/10.1155/2013/729819
Clinical Study

Better Survival with Three-Dimensional Conformal Radiotherapy Than with Conventional Radiotherapy for Cervical Cancer: A Population-Based Study

1Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei 220, Taiwan
2Department of Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
3Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
4Department of Radiation Oncology, Buddhist Dalin Tzu Chi General Hospital, Chiayi 622, Taiwan
5School of Medicine, Tzu Chi University, Hualien 970, Taiwan

Received 4 July 2013; Accepted 27 August 2013

Academic Editors: C. Damodaran and H. M. Warenius

Copyright © 2013 Chen-Hsi Hsieh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Three-dimensional conformal radiation therapy (3DCRT) has emerged as a preferred treatment for gynecologic malignancies. Yet its superiority to conventional radiotherapy (2-dimensional radiotherapy (2DRT)) for gynecologic malignancies has not been well established. Data from the 2005 to 2010 National Health Insurance Research Database (NHIRD) provided by the National Research Institutes in Taiwan were analyzed to address this issue. Patients were initially diagnosed as having cervical cancer according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) code 180, and this clinical diagnosis was confirmed histopathologically or cytologically. Kaplan-Meier method and Cox proportional hazards regression were used to analyze the reported data. Between January 2005 and December 2010, there were 776 patients with newly diagnosed cervical cancer without metastasis, local recurrence, or surgical treatment before RT and 132 and 644 patients, respectively, who received 2DRT and 3DCRT. After adjustment for age, diabetes mellitus, hypertension, coronary heart disease, hyperlipidemia, side effects, urbanization level, geographic region, and enrollee category in the 5-year follow-up period, the HR was 1.82 (95% CI, 1.16–2.85, ). The 5-year survival rate in the 2DRT and 3DCRT groups was 73.0% and 82.3%, , respectively. Cervical cancer patients treated with 3DCRT had better overall survival.